FDA Delays Blood Thinner Eliquis Again
United States Food and Drug Administration officials today delayed approval of Eliquis ( apixaban ) to prevent stroke or systemic embolism in patients with a common heart arrhythmia for the second time.
Drug Drops AFib Stroke Risk
For most patients with a heart rhythm disorder called atrial fibrillation, a procedure that uses electrical currents can successfully restore a normal heart rhythm.
Women with Arrhythmia at Greater Stroke Risk
Women with a common abnormal heartbeat condition called atrial fibrillation are at a greater risk of stroke even if they take anticoagulants to lower their risk. This was especially true for women over the age of 75.
Risk High During Temporary Anticoagulant Halts
Patients with certain types of atrial fibrillation, a common heart arrhythmia, are at a high risk of stroke and blood clots if they temporarily stop their blood thinning medication before surgery or permanently because of side effects.
RA Knocks the Heart Offbeat
Joint pain is not the only thing rheumatoid arthritis patients have to deal with. The disease is linked to a number of other problems, including heart attack and heart failure.
Technology Protects Arrhythmia Patients
An investigational device may help prevent stroke in patients with atrial fibrillation, a common heart arrhythmia that increases the risk of stroke.
New Arrhythmia Drug Boasts Lower Brain Bleeding
Prior to its approval last year, there was much debate about Xarelto ( rivaroxaban ), an anti-clotting drug designed to prevent stroke among patients with atrial fibrillation, a common heart arrhythmia.
Heart Arrhythmias Unknown Stroke Cause
About 33 percent of stroke survivors leave the hospital unsure of the cause. A new finding suggests about 20 percent of strokes with an undetermined cause may have been prompted by a heart arrhythmia episode.
Blood Thinner Pradaxa May Lead to Bleeding
U.S. Food and Drug Administration officials are taking a second look at blood thinning drug Pradaxa ( dabigatran etexilate mesylate ) after reports of serious, potentially fatal, bleeding.
Drug Application for Atrial Fibrillation
Bristol-Myers Squibb Company and Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for Eliquis ( apixaban ), an investigational compound for the prevention of stroke and systemic embolism in patients with atrial fibrillation.